________________________________________________________
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K/A
Amendment No. 1
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
January 23, 2003
----------------
Date of Report
BAXTER INTERNATIONAL INC.
-------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------
(State or other jurisdiction of incorporation)
1-4448 36-0781620
--------------------------- ---------------------------------
(Commission file number) (IRS Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois 60015
--------------------------------------- ------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (847) 948-2000
________________________________________________________
Item 7. Exhibits.
99 Press Release dated January 22, 2003, with corrected attachment.
Item 9. Regulation FD Disclosure
The Key Product Line Sales for 2002 attachment to the press release issued
by the company on January 22, 2003 contained an inadvertent typographical
error. Specifically, the full-year 2002 growth rate for Plasma Proteins
should have been reported as (1%). The full-year 2002 sales for Plasma
Proteins were correctly reported as $1,008,000. The press release,
including the corrected attachment, is filed as Exhibit 99.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BAXTER INTERNATIONAL INC.
-------------------------
(Registrant)
By: /S/ Jan Stern Reed
------------------------------
Jan Stern Reed
Corporate Secretary
Date: January 23, 2003
Exhibit Index
Exhibit No. Description
99 Press Release dated January 22, 2003, with corrected attachment.